ClinicalTrials.gg
RecruitingNCT07268339TRAINUpdated Nov 17, 2026

A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.

A Phase 3 interventional study of radiotherapy and BCG in High-Risk Non-Muscle Invasive Bladder Cancer, sponsored by The Christie NHS Foundation Trust. Recruiting at 2 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by The Christie NHS Foundation Trust · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 17, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United Kingdom — 8 open to participants now, 11 under way, 6 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United Kingdom.

Planned enrollment
6th of 17
328 · median 272
Started
2026
the only one that year
Phase 3
6 of 20
3 open now
Primary completion
2031-12
later than 10 of 10 live
Registered
19th of 20
by date

Among the 20 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United Kingdom, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2026, is one of 6 in phase 3, reaches primary completion later than 10 of the 10 other live ones, and was the 19th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

8 of the 20 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

In the UK 20,000 people develop urothelial bladder cancer each year with 75-80% having Non-Muscle Invasive Bladder Cancer (NMIBC). The current standard of care for patients with High Risk-NMIBC (HR-NMIBC) is either surgery to remove the tumour (transurethral resection of bladder tumour; TURBT) followed by BCG (Bacillus Calmette Guérin, an immunotherapy drug) given directly into the bladder, or surgery to remove the bladder (cystectomy). BCG is given weekly for six weeks followed by maintenance treatment up to 3 years. However, in up to 50% of patients their cancer returns (recurrence) or gets worse (progression) after BCG and 25% stop treatment due to side effects. Globally BCG supply has been restricted in recent years has increased HR-NMIBC recurrence rates and costs. Improved treatments are required, to prevent recurrence, progression and cystectomy, and mitigate the effects of unpredictable supply.

Trimodality treatment (TMT) is maximal TURBT + radiotherapy + a radiosensitiser (gemcitabine, mitomycin C/fluorouracil or carbogen/nicotinamide) and is an equivalent alternative treatment to cystectomy for muscle-invasive bladder cancer (MIBC). TMT is not routinely used for HR-NMIBC. A study found that 54% of HR-NMIBC patients who received TMT did not have recurrence within 5 years. Modern radiotherapy is expected to further improve outcomes and minimise side-effects.

Patients will be randomised 1:1 to BCG or radiotherapy with radiosensitisation. Patients randomised to the experimental arm will receive 55Gy in 20 fractions. Investigators can then choose from three different options for the radiosensitiser. TRAIN will test if radiotherapy with radiosensitisation improves outcomes for people with HR-NMIBC compared to BCG.

TRAIN will recruit 328 patients with HR-NMIBC following maximal TURBT. All patients will be followed up for a minimum of two years to record their response to treatment.

03

Conditions studied

  • High-Risk Non-Muscle Invasive Bladder Cancer

Keywords

  • non-muscle invasive bladder cancer
  • radiotherapy with radiosensitisation drugs
  • Bacillus Calmette-Guerin therapy
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with confirmed grade 3 T1 N0 M0 transitional cell carcinoma, OR carcinoma in situ of the bladder (and N0 M0), OR both, with detrusor muscle present in the specimen if T1 disease (or a repeat resection that does contain muscle that is clear)
  • Suitable for BCG treatment
  • Suitable for radiotherapy and radiosensitisation according to the schedule of administration outlined in the Radiotherapy Planning Guidance document.
  • over 12 months
  • performance status 0 - 2
  • Age >=16 years
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • MDT selected patients with HR-NMIBC who are deemed best suited for primary cystectomy (patients that have had this treatment recommendation but then decline cystectomy remain eligible for TRAIN)
  • Previous radiotherapy to the pelvis
  • Previous intravesical therapy
  • Poor bladder function (IPSS >16)
  • A recent or current other cancer. Current non-melanoma skin cancer, cervical carcinoma in situ or localized prostate cancer not requiring current treatment are permissible, as is a history of a separate other having completed all active treatment ≥2 years previously and without evidence of relapse
  • Pre-existing medical conditions that preclude treatment options in either trial arm
  • Patient currently recruited to another interventional trial or participation within an interventional clinical trial within 3 months of the point of registration within TRAIN.
  • Pregnant or breast-feeding
  • Not able to use appropriate adequate effective during and for 3 months after the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
328 participants (estimated)

Study arms

  • Active comparator
    Control Arm: BCG

    This arm is standard of care for this patient group. A standard protocol of 6 weekly intravesical installations, followed by 3 weekly instillations at approximately 3, 6, 12, 18, 24, 30 months and 36 months (depending on toxicity). Stock is taken and given per local hospital guildlines.

    Other: BCG

  • Experimental
    Experimental Arm: Radiotherapy with Radiosentiser drugs.

    Patients randomised to the radiotherapy arm will receive a hypofractionated schedule of external beam radiotherapy with a regimen of 55Gy in 20 fractions given once daily Monday to Friday over 4 weeks. Radiotherapy will be delivered with a conventional or 3D conformal technique with an empty bladder. It will be administered concurrently with a radiosensitiser (detailed below) selected by the treating physician according to local institutional practice. Radiosensitiser will be selected as one option from the following: * Gemcitabine 75-100mg/m2 administered once a week during a four-week radiotherapy course. Cycle 1 will be given on the first radiotherapy day, to a planned total of 4 cycles. 2-4 hours prior to radiotherapy * 5-FU and Mitomycin C - Fluorouracil 500mg/m2 Days 1-5 and 16-20 via continuous infusion. Mitomycin C 12mg/m2 Day 1 via intravenous infusion * Carbogen and nicotinamide (CON) - 2% CO2 and 98% O2 Carbogen will be delivered through a closed breathing system with

    Radiation: radiotherapy

Interventions

  • Radiationradiotherapy

    Radiotherapy - 55Gy in 20 fractions treating once daily Monday to Friday over 4 weeks.

  • OtherBCG

    BCG protocol of 6 weekly intravesical instillations, followed by 3 weekly instillations at 3, 6, 12, 18, 24, 30, 36 months.

06

What researchers measure

Primary outcomes

  1. To compare event-free survival between BCG and radiotherapy with radiosensitisation.

    Event-free survival is defined as recurrence of CIS or high-risk non-muscle invasive papillary tumour, continued presence of HR NMIBC even after treatment completion, progression to muscle-invasive disease, distant metastatic bladder cancer, cystectomy (for any reason) or death from any cause.

    Time frame: From baseline to at least 96 weeks after initial of treatment.

Secondary outcomes

  1. To determine the difference between BCG and radiotherapy in terms of patient-reported symptoms.

    Patient-reported outcomes will be assessed via questionnaires, including the RTOG (late bladder and intestinal toxicity) questionnaire.

    Time frame: From baseline to at least 96 weeks post treatment.

  2. To evaluate each component of the primary outcome comparing between BCG and radiotherapy with radiosensitisation.

    The following event outcomes will be analyzed using the Cox proportional hazards model to estimate hazard ratios, and Kaplan-Meier analysis will be used to estimate event rates. * Recurrence-free survival (RFS) defined as time from randomisation to recurrence of non-muscle invasive papillary tumour. Patients are censored at the last follow-up if event free. * Progression-free survival (PFS) defined as time from randomisation to progression to muscle-invasive disease. Patients are censored at the last follow-up if event free. * Metastasis-free survival (MFS) defined as time from randomisation to progression to distant metastatic bladder cancer. Patients are censored at the last follow-up if event free. * Cystectomy-free survival (CFS) defined as time from randomisation to cystectomy. Patients are censored at the last follow-up if event free * Overall survival (OS) defined as time from randomisation to death due to any cause. Patients are censored at the last follow-up if event free

    Time frame: From baseline to at least 96 weeks post treatment.

  3. To establish the tolerability and safety of radiotherapy.

    MedDRA coded adverse events graded using CTCAE v5.0.

    Time frame: From baseline to at least end of 4 week treatment.

  4. To determine the difference in cancer specific survival between groups.

    Cancer specific survival defined as time from randomisation to death from cancer. Patients who die of a cause other than the cancer under study or who are lost to follow-up are censored at death or the last date on which they were known to be alive.

    Time frame: From baseline to at least 96 weeks post treatment.

  5. To determine the difference in treatment fidelity between the groups.

    Treatment fidelity defined as how well each group implemented treatment as intended. Summary statistics will be presented for any treatment delays, missed treatment, those not starting treatment, and those who completed treatment, by group.

    Time frame: From baseline to at least 96 weeks post treatment.

  6. To determine the cost-effectiveness of radiotherapy with radiosensitisation compared to BCG.

    * Within trial analysis. Total costs and QALYs for radiotherapy with radiosensitisation compared to BCG during the trial period. * Economic modelling. Total costs and QALYs for radiotherapy with radiosensitisation compared to BCG extrapolated beyond the trial period.

    Time frame: From Baseline to at least 96 weeks post treatment.

  7. To determine the difference between BCG and radiotherapy in terms of patient-reported symptoms.

    Patient-reported outcomes will be assessed via questionnaires, including the EQ-5D questionnaire.

    Time frame: From baseline to at least 96 weeks post treatment.

  8. To determine the difference between BCG and radiotherapy in terms of patient-reported symptoms.

    Patient-reported outcomes will be assessed via questionnaires, including the IPSS questionnaire.

    Time frame: From baseline to at least 96 weeks post treatment.

  9. To determine the difference between BCG and radiotherapy in terms of patient-reported symptoms.

    Patient-reported outcomes will be assessed via questionnaires, including the QLQ-C30 questionnaire.

    Time frame: From baseline to at least 96 weeks post treatment.

  10. To determine the difference between BCG and radiotherapy in terms of patient-reported symptoms.

    Patient-reported outcomes will be assessed via questionnaires, including the QLQ-NMIBC24 questionnaire.

    Time frame: From baseline to at least 96 weeks post treatment.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data will be made available, including data dictionaries, for approved data-sharing requests. Individual participant data will be shared that underlie the results reported in this article, after de-identification and normalisation of information (text, tables, figures, and appendices). The study protocol and statistical analysis plan will also be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Anonymous data will be available for request from three months after publication of the article, to researchers who provide a completed Data Sharing request form that describes a methodologically sound proposal, for the purpose of the approved proposal and if appropriate, signed a Data Sharing Agreement.

Access criteria: Data will be shared once all parties have signed relevant data-sharing documentation, covering SCTU conditions for sharing and if required, an additional Data Sharing Agreement from Sponsor. Proposals should be directed to ctu@soton.ac.uk.

Data sharing details ↗ · www.southampton.ac.uk

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Dec 2031, 67 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Apr 2026, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Dec 5, 2025
StartActual
Apr 24, 2026was Dec 2025
Primary completionEst.
Dec 1, 2031
CompletionEst.
Dec 1, 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
1 site added. The Christie is now Recruiting
Show site
  • Tameside General Hospital · Manchester, United Kingdom
Nov 17, 2026
Start date
Dec 1, 2025→Apr 24, 2026 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    1 site added. The Christie is now Recruiting
    Show site
    • Tameside General Hospital · Manchester, United Kingdom
    Start date Dec 1, 2025→Apr 24, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07268339
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Apr 24, 2026
Primary completion
Dec 1, 2031 (estimated)
Completion
Dec 1, 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Amber B Cole
Contact
train@soton.ac.uk
023 8120 5154
Daniel Griffiths
Contact
train@soton.ac.uk
023 8120 5154

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion